DE60035871D1 - Expression und export von interferon-alpha proteinen als fc fusionsproteine - Google Patents

Expression und export von interferon-alpha proteinen als fc fusionsproteine

Info

Publication number
DE60035871D1
DE60035871D1 DE60035871T DE60035871T DE60035871D1 DE 60035871 D1 DE60035871 D1 DE 60035871D1 DE 60035871 T DE60035871 T DE 60035871T DE 60035871 T DE60035871 T DE 60035871T DE 60035871 D1 DE60035871 D1 DE 60035871D1
Authority
DE
Germany
Prior art keywords
interferon
alpha
proteins
nucleic acid
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60035871T
Other languages
English (en)
Other versions
DE60035871T2 (de
Inventor
Kin-Ming Lo
Yaping Sun
Stephen D Gillies
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
EMD Serono Research Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EMD Serono Research Center Inc filed Critical EMD Serono Research Center Inc
Publication of DE60035871D1 publication Critical patent/DE60035871D1/de
Application granted granted Critical
Publication of DE60035871T2 publication Critical patent/DE60035871T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
DE60035871T 1999-05-19 2000-05-19 Expression und export von interferon-alpha proteinen als fc fusionsproteine Expired - Lifetime DE60035871T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13489599P 1999-05-19 1999-05-19
US134895P 1999-05-19
PCT/US2000/013827 WO2000069913A1 (en) 1999-05-19 2000-05-19 EXPRESSION AND EXPORT OF INTERFERON-ALPHA PROTEINS AS Fc FUSION PROTEINS

Publications (2)

Publication Number Publication Date
DE60035871D1 true DE60035871D1 (de) 2007-09-20
DE60035871T2 DE60035871T2 (de) 2008-06-05

Family

ID=22465500

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60035871T Expired - Lifetime DE60035871T2 (de) 1999-05-19 2000-05-19 Expression und export von interferon-alpha proteinen als fc fusionsproteine

Country Status (22)

Country Link
US (2) US20020081664A1 (de)
EP (1) EP1187852B1 (de)
JP (1) JP2003530070A (de)
KR (1) KR20020018197A (de)
CN (1) CN1361793A (de)
AT (1) ATE369384T1 (de)
AU (1) AU777963B2 (de)
BR (1) BR0010725A (de)
CA (1) CA2372400C (de)
CZ (1) CZ20014123A3 (de)
DE (1) DE60035871T2 (de)
DK (1) DK1187852T3 (de)
ES (1) ES2291205T3 (de)
HK (1) HK1046694A1 (de)
HU (1) HUP0201474A3 (de)
MX (1) MXPA01011845A (de)
NO (1) NO20015587L (de)
PL (1) PL352332A1 (de)
PT (1) PT1187852E (de)
RU (1) RU2262510C9 (de)
WO (1) WO2000069913A1 (de)
ZA (1) ZA200109227B (de)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1037927B1 (de) 1997-12-08 2004-05-19 Lexigen Pharmaceuticals Corp. Heterodimäre fusionsproteine zur verwendung für gezielte immuntherapie und allgemeine immunerregung
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
JP2002511432A (ja) * 1998-04-15 2002-04-16 レキシジェン ファーマシューティカルズ コーポレイション 新脈管形成インヒビターの同時投与による抗体−サイトカイン融合タンパク質媒介性免疫応答の増強
PT1187852E (pt) * 1999-05-19 2007-11-14 Merck Patent Gmbh Expressão e exportação de proteínas interferão-alfa na forma de proteínas de fusão com fc
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
MXPA02001417A (es) * 1999-08-09 2002-08-12 Lexigen Pharm Corp Complejos multiples de citosina-anticuerpo.
US20050202538A1 (en) * 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
AU4314801A (en) * 2000-02-11 2001-08-20 Lexigen Pharm Corp Enhancing the circulating half-life of antibody-based fusion proteins
CA2747325A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
CN1270775C (zh) * 2000-06-29 2006-08-23 默克专利有限公司 通过与免疫细胞因子摄入促进剂联合治疗来增强抗体－细胞因子融合蛋白介导的免疫反应
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
KR100900176B1 (ko) * 2001-03-07 2009-06-02 메르크 파텐트 게엠베하 하이브리드 이소타입 항체 부분구조를 포함하는 단백질을위한 발현 기술
US6992174B2 (en) * 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
WO2002088161A1 (en) * 2001-05-02 2002-11-07 Pepgen Corporation Method for expression of human interferon alpha 1 in pichia pa storis
DK1383785T3 (da) * 2001-05-03 2011-05-23 Merck Patent Gmbh Rekombinant tumorspecifikt antistof og anvendelse deraf
AU2002357784B2 (en) 2001-12-04 2008-07-31 Merck Patent Gmbh Immunocytokines with modulated selectivity
EP1463751B1 (de) 2001-12-21 2013-05-22 Human Genome Sciences, Inc. Albuminfusionsproteine
US7314613B2 (en) 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
CA2504267A1 (en) * 2002-11-18 2004-06-03 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
PT1572748E (pt) * 2002-12-17 2010-09-28 Merck Patent Gmbh Anticorpo humanizado (h14.18) do anticorpo 14.18 de rato que se liga ao gd2 e a sua fusão com a il-2
WO2004074486A2 (en) * 2003-02-18 2004-09-02 Merck Patent Gmbh Fusion proteins of interferon alpha muteins with improved properties
US20050176108A1 (en) * 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
US20040180054A1 (en) * 2003-03-13 2004-09-16 Hanmi Pharm. Co., Ltd. Physiologically active polypeptide conjugate having prolonged in vivo half-life
DK2298347T3 (en) * 2003-05-06 2016-01-11 Biogen Hemophilia Inc COAGULATION FACTOR CHEMICAL PROTEINS FOR TREATING A HEMOSTATIC DISORDER
US7348004B2 (en) * 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
AU2004238263A1 (en) * 2003-05-06 2004-11-25 Syntonix Pharmaceuticals, Inc. Inhibition of drug binding to serum albumin
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US20050069521A1 (en) * 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
US8383132B2 (en) * 2003-10-16 2013-02-26 The Regents Of The University Of California Immunostimulatory recombinant intracellular pathogen immunogenic compositions and methods of use
EP2385069A3 (de) 2003-11-12 2012-05-30 Biogen Idec MA Inc. Neonataler Fc-Rezeptor (FcRn)-bindende Polypeptidvarianten, dimere Fc-Bindungsproteine und damit in Zusammenhang stehende Verfahren
EP2256134B1 (de) * 2003-11-13 2014-01-08 Hanmi Science Co., Ltd. IgG-Fc-Fragment für einen Arzneimittelträger und Verfahren zu dessen Herstellung
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
BRPI0418286A (pt) 2003-12-30 2007-05-02 Merck Patent Gmbh proteìnas de fusão de il-7
CA2551916C (en) * 2003-12-31 2014-04-29 Merck Patent Gesellschaft Mit Beschraenkter Haftung Fc-erythropoietin fusion protein with improved pharmacokinetics
AU2005203962C1 (en) 2004-01-05 2012-11-08 Antisoma Research Limited Interleukin-12 targeted to oncofoetal fibronectin
CA2553883C (en) 2004-01-22 2013-04-02 Merck Patent Gesellschaft Mit Beschraenkter Haftung Anti-cancer antibodies with reduced complement fixation
BRPI0507169A (pt) 2004-02-02 2007-06-26 Ambrx Inc polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
AU2008201682B2 (en) * 2004-02-02 2011-02-24 Ambrx, Inc. Modified human interferon polypeptides and their uses
BRPI0511196A (pt) 2004-05-19 2007-12-04 Maxygen Inc polipeptìdeo isolado ou recombinante, conjugado, composição, célula hospedeira, vetor, métodos para preparar um polipeptìdeo, para preparar um conjugado, para reduzir o número de cópias de um vìrus em células infectadas com o vìrus, para reduzir o nìvel de rna hcv, dna hbv e rna hiv no soro de um paciente infectado com hcv, hbv e hiv, e, uso do polipeptìdeo, do conjugado ou da composição
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
ES2381557T3 (es) 2004-08-03 2012-05-29 Innate Pharma Métodos terapéuticos y de diagnóstico y composiciones para determinar 4IG-B7-H3 y su receptor homólogo en las células NK
EP1819728B1 (de) * 2004-12-09 2010-04-21 MERCK PATENT GmbH Il-7-varianten mit reduzierter immunogenität
KR20070100346A (ko) 2005-01-05 2007-10-10 바이오겐 아이덱 엠에이 인코포레이티드 크립토 결합 분자
US20170121692A1 (en) * 2005-04-06 2017-05-04 Ibc Pharmaceuticals, Inc. Methods for Generating Stably Linked Complexes Composed of Homodimers, Homotetramers or Dimers of Dimers and Uses
US8158129B2 (en) * 2005-04-06 2012-04-17 Ibc Pharmaceuticals, Inc. Dimeric alpha interferon PEGylated site-specifically shows enhanced and prolonged efficacy in vivo
US7619067B2 (en) 2005-05-18 2009-11-17 Maxygen, Inc. Evolved interferon-alpha polypeptides
US7566456B2 (en) * 2005-06-23 2009-07-28 Haiming Chen Allergen vaccine proteins for the treatment and prevention of allergic diseases
CN105012953B (zh) 2005-07-25 2018-06-22 阿普泰沃研发有限责任公司 用cd37-特异性和cd20-特异性结合分子减少b-细胞
AU2006280587B2 (en) 2005-08-16 2011-02-24 Hanmi Science Co., Ltd. A method for the mass production of immunoglobulin Fc region deleted initial methionine residues
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
CN101351475B (zh) * 2005-12-30 2013-05-15 默克专利有限公司 具有提高的稳定性的白细胞介素12p40变体
EP1966245B1 (de) 2005-12-30 2011-05-18 Merck Patent GmbH Anti-cd19-antikörper mit reduzierter immunogenität
CA2654317A1 (en) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
EP2061515A4 (de) 2006-09-14 2013-01-30 Medgenics Medical Israel Ltd Heilmittelformulierungen mit langzeitwirkung
US8454948B2 (en) 2006-09-14 2013-06-04 Medgenics Medical Israel Ltd. Long lasting drug formulations
CN1944463B (zh) * 2006-10-30 2010-05-12 中国科学技术大学 具有α干扰素活性的融合蛋白及其编码基因与应用
EP2365003A1 (de) 2008-04-11 2011-09-14 Emergent Product Development Seattle, LLC CD37-Immuntherapeutikum und Kombination mit bifunktionellem Chemotherapeutikum davon
CA2759333A1 (en) 2009-04-22 2010-10-28 Merck Patent Gmbh Antibody fusion proteins with modified fcrn binding sites
WO2011064758A2 (en) * 2009-11-30 2011-06-03 Pfizer Limited Fusion protein
ME03091B (de) 2009-12-01 2019-01-20 Translate Bio Inc Ausgabe von mrna zur vermehrung von proteinen und enzymen bei humangenetischen erkrankungen
EP2582396A4 (de) 2010-06-15 2014-01-01 Medgenics Medical Israel Ltd Heilmittelformulierungen mit langzeitwirkung
CN102585013B (zh) * 2011-01-07 2014-04-23 中国人民解放军军事医学科学院生物工程研究所 一种含有ω干扰素的融合蛋白及制备方法
EP2718457A4 (de) * 2011-06-06 2014-12-24 Immungene Inc Manipulierte ligandenfusionsmoleküle mit einem antikörper-tnfsf-element
EP2717893B1 (de) 2011-06-08 2019-05-08 Translate Bio, Inc. Lipidnanoteilchenzusammensetzungen und verfahren zur mrna-freisetzung
EP2859102A4 (de) 2012-06-08 2016-05-11 Shire Human Genetic Therapies Nukleaseresistente polynukleotide und verwendungen davon
US8784834B2 (en) 2012-07-24 2014-07-22 Sbc Virbac Biotech Co., Ltd. Recombinant fusion interferon for animals
US8956623B2 (en) 2012-07-24 2015-02-17 Sbc Virbac Limited Recombinant fusion interferon for animals
EP2970940B1 (de) * 2013-03-14 2018-07-25 Translate Bio, Inc. Therapeutische mrna-zusammensetzungen und verwendung zur behandlung von krankheiten und störungen
WO2014152966A1 (en) 2013-03-14 2014-09-25 Shire Human Genetic Therapies, Inc. Methods for purification of messenger rna
CN105142676B (zh) 2013-03-14 2022-06-28 夏尔人类遗传性治疗公司 Cftr mrna组合物以及相关方法和用途
LT6164B (lt) 2013-10-15 2015-06-25 Uab Biotechnologinės Farmacijos Centras "Biotechpharma" Sulieti interferono-alfa 5 baltymai su kitu citokinu ir jų gamybos būdas
CN106413811A (zh) 2013-10-22 2017-02-15 夏尔人类遗传性治疗公司 精氨基琥珀酸合成酶缺乏症的mrna疗法
MX2016005239A (es) 2013-10-22 2016-08-12 Shire Human Genetic Therapies Tratamiento con acido ribonucleico mensajero para la fenilcetonuria.
EA201691696A1 (ru) 2014-04-25 2017-03-31 Шир Хьюман Дженетик Терапис, Инк. Способы очистки матричной рнк
EA201890613A1 (ru) 2015-09-21 2018-10-31 Аптево Рисёрч Энд Девелопмент Ллс Полипептиды, связывающие cd3
US11661455B2 (en) * 2016-02-05 2023-05-30 Orionis Biosciences BV Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety
MA47603A (fr) 2017-02-27 2020-01-01 Translate Bio Inc Nouvel arnm cftr à codons optimisés
EP3600379B1 (de) 2017-03-31 2022-12-21 Accanis Biotech F&E GmbH & Co KG Vorbeugung und behandlung von nichtmelanom-hautkrebs (nmsc)
US11173190B2 (en) 2017-05-16 2021-11-16 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of codon-optimized mRNA encoding CFTR
RU2650755C1 (ru) * 2017-05-24 2018-04-17 Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России (ФГБУ "ГНЦ Институт иммунологии" ФМБА России) Способ очистки лекарственного средства пролонгированного действия на основе рекомбинантного аналога интерферона альфа-17 для лечения вирусного гепатита С
CN107254482A (zh) * 2017-07-18 2017-10-17 哈尔滨紫霞生物科技有限公司 一种提高重组猪干扰素‑α融合蛋白抗病毒活性的方法
CN108727504B (zh) * 2018-04-16 2021-08-27 泉州向日葵生物科技有限公司 一种ifn与抗pd-l1抗体的融合蛋白及其应用
CU24554B1 (es) * 2018-05-07 2021-11-04 Ct Inmunologia Molecular Proteínas de fusión compuestas por una muteína de interleucina 2 e interferón tipo 1
US11174500B2 (en) 2018-08-24 2021-11-16 Translate Bio, Inc. Methods for purification of messenger RNA
EP3955957A1 (de) 2019-04-15 2022-02-23 Qwixel Therapeutics LLC Fusionsproteinzusammensetzung(en) mit gezielten maskierten typ-i-interferonen (ifna und ifnb) und einem antikörper gegen tumorantigene zur verwendung bei der behandlung von krebs
RU2764787C1 (ru) * 2020-12-08 2022-01-21 Федеральное государственное бюджетное научное учреждение "Федеральный исследовательский центр фундаментальной и трансляционной медицины" (ФИЦ ФТМ) Рекомбинантная плазмидная ДНК, кодирующая химерный интерферон alpha2b, рекомбинантный штамм дрожжей P. pastoris X33 - продуцент химерного интерферона alpha2b и способ получения указанного белка

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) * 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4469797A (en) * 1982-09-23 1984-09-04 Miles Laboratories, Inc. Digoxigenin immunogens, antibodies, labeled conjugates, and related derivatives
US4966843A (en) * 1982-11-01 1990-10-30 Cetus Corporation Expression of interferon genes in Chinese hamster ovary cells
US5082658A (en) * 1984-01-16 1992-01-21 Genentech, Inc. Gamma interferon-interleukin-2 synergism
US5679543A (en) * 1985-08-29 1997-10-21 Genencor International, Inc. DNA sequences, vectors and fusion polypeptides to increase secretion of desired polypeptides from filamentous fungi
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4935233A (en) * 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5359035A (en) * 1985-12-21 1994-10-25 Hoechst Aktiengesellschaft Bifunctional proteins including interleukin-2 (IL-2) and granuloctyte macrophage colony stimulating factor (GM-CSF)
US5019368A (en) * 1989-02-23 1991-05-28 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
EP0307434B2 (de) * 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Geänderte antikörper
US4732462A (en) * 1987-04-27 1988-03-22 Ronald Bel Safety viewing apparatus for crane car
US5091513A (en) * 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) * 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5120525A (en) * 1988-03-29 1992-06-09 Immunomedics, Inc. Radiolabeled antibody cytotoxic therapy of cancer
US5601819A (en) * 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US6750329B1 (en) * 1989-05-05 2004-06-15 Research Development Foundation Antibody delivery system for biological response modifiers
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
EP0406857B1 (de) * 1989-07-07 1995-05-24 Takeda Chemical Industries, Ltd. Proteine und deren Herstellung
US5314995A (en) * 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
US5349053A (en) * 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
US7253264B1 (en) * 1990-06-28 2007-08-07 Sanofi-Arentideutschland GmbH Immunoglobulin fusion proteins, their production and use
US5650150A (en) * 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
US5709859A (en) * 1991-01-24 1998-01-20 Bristol-Myers Squibb Company Mixed specificity fusion proteins
US20020037558A1 (en) * 1991-10-23 2002-03-28 Kin-Ming Lo E.coli produced immunoglobulin constructs
US6627615B1 (en) * 1991-12-17 2003-09-30 The Regents Of The University Of California Methods and compositions for in vivo gene therapy
WO1993024135A1 (en) * 1992-05-26 1993-12-09 Immunex Corporation Novel cytokine that binds cd30
WO1993024640A2 (en) * 1992-06-04 1993-12-09 The Regents Of The University Of California Methods and compositions for in vivo gene therapy
US5614184A (en) * 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
EP0671926B1 (de) * 1992-08-11 2002-11-13 President And Fellows Of Harvard College Immunmodulierende peptide
DE4228839A1 (de) * 1992-08-29 1994-03-03 Behringwerke Ag Verfahren zum Nachweis und zur Bestimmung von Mediatoren
US5554512A (en) * 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US6086875A (en) * 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US6485726B1 (en) * 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
AU712585B2 (en) * 1995-03-10 1999-11-11 Genentech Inc. Receptor activation by gas6
US6281010B1 (en) * 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
US6620413B1 (en) * 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
US6750334B1 (en) * 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
EP0826696B1 (de) * 1996-09-03 2002-05-29 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Verwendung bi-und trispezifischer Antikörper zur Induktion einer Tumorimmunität
US6100387A (en) * 1997-02-28 2000-08-08 Genetics Institute, Inc. Chimeric polypeptides containing chemokine domains
US6277375B1 (en) * 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
EP1037927B1 (de) * 1997-12-08 2004-05-19 Lexigen Pharmaceuticals Corp. Heterodimäre fusionsproteine zur verwendung für gezielte immuntherapie und allgemeine immunerregung
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
US6284536B1 (en) * 1998-04-20 2001-09-04 The Regents Of The University Of California Modified immunoglobin molecules and methods for use thereof
AU770555B2 (en) * 1998-08-17 2004-02-26 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
US6646113B1 (en) * 1998-09-17 2003-11-11 The Trustees Of The University Of Pennsylvania Nucleic acid molecule encoding human survival of motor neuron-interacting protein 1 (SIP1) deletion mutants
US6335176B1 (en) * 1998-10-16 2002-01-01 Pharmacopeia, Inc. Incorporation of phosphorylation sites
DE60041183D1 (de) * 1999-05-06 2009-02-05 Univ Wake Forest Zusammensetzungen und methoden zur identifikation von antigenen, die eine immunantwort hervorrufen
PT1187852E (pt) * 1999-05-19 2007-11-14 Merck Patent Gmbh Expressão e exportação de proteínas interferão-alfa na forma de proteínas de fusão com fc
MXPA02001417A (es) * 1999-08-09 2002-08-12 Lexigen Pharm Corp Complejos multiples de citosina-anticuerpo.
AU4314801A (en) * 2000-02-11 2001-08-20 Lexigen Pharm Corp Enhancing the circulating half-life of antibody-based fusion proteins
HUP0302299A2 (hu) * 2000-05-12 2003-10-28 Neose Technologies, Inc. Rekombináns glikopeptidek glikozilezési mintázatának in vitro módosítása
CN1270775C (zh) * 2000-06-29 2006-08-23 默克专利有限公司 通过与免疫细胞因子摄入促进剂联合治疗来增强抗体－细胞因子融合蛋白介导的免疫反应
KR100900176B1 (ko) * 2001-03-07 2009-06-02 메르크 파텐트 게엠베하 하이브리드 이소타입 항체 부분구조를 포함하는 단백질을위한 발현 기술
DK1383785T3 (da) * 2001-05-03 2011-05-23 Merck Patent Gmbh Rekombinant tumorspecifikt antistof og anvendelse deraf

Also Published As

Publication number Publication date
HK1046694A1 (zh) 2003-01-24
NO20015587D0 (no) 2001-11-15
AU777963B2 (en) 2004-11-04
PT1187852E (pt) 2007-11-14
JP2003530070A (ja) 2003-10-14
ATE369384T1 (de) 2007-08-15
ZA200109227B (en) 2003-02-03
HUP0201474A2 (en) 2002-08-28
US20050042729A1 (en) 2005-02-24
ES2291205T3 (es) 2008-03-01
WO2000069913A1 (en) 2000-11-23
DK1187852T3 (da) 2007-11-26
HUP0201474A3 (en) 2002-11-28
AU5031800A (en) 2000-12-05
CZ20014123A3 (cs) 2002-06-12
RU2262510C2 (ru) 2005-10-20
MXPA01011845A (es) 2002-06-21
US20020081664A1 (en) 2002-06-27
EP1187852A1 (de) 2002-03-20
BR0010725A (pt) 2002-02-19
KR20020018197A (ko) 2002-03-07
EP1187852B1 (de) 2007-08-08
DE60035871T2 (de) 2008-06-05
PL352332A1 (en) 2003-08-11
NO20015587L (no) 2002-01-16
CA2372400A1 (en) 2000-11-23
RU2262510C9 (ru) 2006-04-20
CA2372400C (en) 2010-04-27
CN1361793A (zh) 2002-07-31

Similar Documents

Publication Publication Date Title
ATE369384T1 (de) Expression und export von interferon-alpha proteinen als fc fusionsproteine
WO2000040615A3 (en) EXPRESSION AND EXPORT OF ANTI-OBESITY PROTEINS AS Fc FUSION PROTEINS
AP1678A (en) Novel modified nucleic acid sequences and methods for increasing mRNA levels and protein expression in cell systems.
DE69636890D1 (de) Neuartige ctla4/cd28 liganden und deren anwendungen
DE69635864D1 (de) Rekombinante rna-replikase von hepatitis-c-virus
ATE443074T1 (de) Zubereitungen und methoden zur verwendung in rekombinatorischem klonen von nukleinsäuren
DK0724642T4 (da) Nucleinsyrevektor, sammensætning indeholdende en sådan vektor og vaccine til immunisering mod hepatitis
DK0550687T3 (da) 5' til 3'-exonukleasemutationer af termostabile DNA-polymeraser
Moise et al. T4 gene 32 protein model for control of activity at replication fork
ATE341621T1 (de) Rekombinatorisches klonieren unter verwendung von nukleinsaüren mit rekombinationsstellen
WO2000011033A3 (en) Expression and export of angiostatin and endostatin as immunofusins
ATE482714T1 (de) Modifizierter hitzeschockprotein-antigenpeptid- komplex
HUP9800329A2 (hu) Nukleinsavkonstrukciók strukturális gének sejtciklus-függő módon szabályozott expresszálására
Gillen et al. Characterization of the deoxyribonuclease determined by lambda reverse as exonuclease VIII of Escherichia coli
DE69834565D1 (de) Schnell erzeugung von stabilen säugertier-zellinien mit gewinnung eines hohen gehalts von recombinanten proteine
CY1107431T1 (el) Σωματιδια για γoνιδιακη θεραπεια
DE69637154D1 (de) Hocheffizientes gewebespezifisches system zur bereitstellung von verbindungen unter verwendung eines streptavidin-protein a fusionsproteins
WO1993017031A3 (en) Nucleic acids encoding dystrophin-associated proteins
DE59712771D1 (de) Nebenhoden-spezifisches Rezeptorprotein und dessen Verwendung
DK326289A (da) Fremgangsmaade til fremstilling af et protein ud fra gaersvampe under anvendelse af et inducerbart system, samt vektorer og transformerede stammer til brug ved fremgangsmaaden
EP0789563B8 (de) Impfstoffe gegen den hepatitis b und c virus
Weideli et al. A New Method for the Purification of DNA‐Binding Proteins with Sequence Specificity
KR940021732A (ko) C형 간염 바이러스의 비구조 4 부분 단백질의 발현
WO2002006485A3 (en) 47885, a novel human ubiquitin-activating enzyme and uses therefor
ATE547427T1 (de) Verfahren zur rekombinanten herstellung von ribonukleoproteinen

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: MERCK PATENT GMBH, 64293 DARMSTADT, DE

8364 No opposition during term of opposition